Gilead Sciences (GILD) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order by the Chairman and CEO, with introductions of board members, executive team, and independent auditor present.

• Formal business conducted as per proxy statement, with procedures and technical support outlined for virtual participation.

• Inspector of Election appointed and sworn in to oversee voting.

• Quorum established with proxies for 91.1% of outstanding shares.

Board and executive committee updates

• Nine director nominees, all current directors, were up for election for the next year.

• Board recommended in favor of all director nominees and key proposals, except for certain shareholder proposals.

Shareholder proposals

• Proposal for an independent board chair policy presented, citing improved governance and long-term performance; board opposed.

• Proposal for a report on the impact of extended patent exclusivities on patient access discussed, highlighting reputational and financial risks; board opposed.

• Proposal for a report on risks of ESG and DEI executive compensation metrics presented, emphasizing focus on fiduciary duty and minimizing political influence; board opposed.